10-Q Filing

BIO-PATH HOLDINGS, INC. CIK: 1133818 Q1 2020

Filing Information

Form Type	10-Q
Accession Number	`0001104659-20-061598`
Period End Date	20200331
Filing Date	20200514
Fiscal Year	2020
Fiscal Period	Q1
XBRL Instance	bpth-20200331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 60 Income Statement 18 Cash Flow Statement 37 Stockholders Equity 14

Balance Sheet 60 line items

Line Item	Tag	Value	Unit	Period
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash	`Cash`	$20.43M	USD	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash	`Cash`	$17.89M	USD	Point-in-time
Prepaid drug product for testing	`PrepaidExpenseCurrent`	$776.00K	USD	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Prepaid drug product for testing	`PrepaidExpenseCurrent`	$764.00K	USD	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$788.00K	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$538.00K	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$21.99M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$19.19M	USD	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	3.69M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	3.69M	shares	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	3.69M	shares	Point-in-time
Furniture, fixtures & equipment	`PropertyPlantAndEquipmentGross`	$1.03M	USD	Point-in-time
Furniture, fixtures & equipment	`PropertyPlantAndEquipmentGross`	$1.03M	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	3.69M	shares	Point-in-time
Less accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$744.00K	USD	Point-in-time
Less accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$726.00K	USD	Point-in-time
Furniture, fixtures & equipment, net	`PropertyPlantAndEquipmentNet`	$303.00K	USD	Point-in-time
Furniture, fixtures & equipment, net	`PropertyPlantAndEquipmentNet`	$285.00K	USD	Point-in-time
Right of use operating assets	`OperatingLeaseRightOfUseAsset`	$367.00K	USD	Point-in-time
Right of use operating assets	`OperatingLeaseRightOfUseAsset`	$348.00K	USD	Point-in-time
Total Assets	`Assets`	$22.66M	USD	Point-in-time
Total Assets	`Assets`	$19.83M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$818.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$486.00K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$682.00K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$673.00K	USD	Point-in-time
Current portion of lease liabilities	`OperatingLeaseLiabilityCurrent`	$85.00K	USD	Point-in-time
Current portion of lease liabilities	`OperatingLeaseLiabilityCurrent`	$87.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.24M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.59M	USD	Point-in-time
Noncurrent lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$330.00K	USD	Point-in-time
Noncurrent lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$307.00K	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.57M	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.89M	USD	Point-in-time
Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $.001 par value; 200,000 shares authorized; 3,692 and 3,692 shares issued and outstanding, respectively	`CommonStockValue`	$4.00K	USD	Point-in-time
Common stock, $.001 par value; 200,000 shares authorized; 3,692 and 3,692 shares issued and outstanding, respectively	`CommonStockValue`	$4.00K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$77.59M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$77.42M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-59.66M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-56.34M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$21.09M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$17.93M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$20.14M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$1.22M	USD	Point-in-time
Total Liabilities & Shareholders' Equity	`LiabilitiesAndStockholdersEquity`	$22.66M	USD	Point-in-time
Total Liabilities & Shareholders' Equity	`LiabilitiesAndStockholdersEquity`	$19.83M	USD	Point-in-time

Income Statement 18 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$2.01M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$398.00K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$1.34M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$1.12M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$1.52M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$3.34M	USD	1 Quarter
Net operating loss	`OperatingIncomeLoss`	$-1.52M	USD	1 Quarter
Net operating loss	`OperatingIncomeLoss`	$-3.34M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$8.00K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$20.00K	USD	1 Quarter
Total other income	`NonoperatingIncomeExpense`	$20.00K	USD	1 Quarter
Total other income	`NonoperatingIncomeExpense`	$8.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.51M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-3.32M	USD	1 Quarter
Net loss per share, basic and diluted (in dollars)	`EarningsPerShareBasicAndDiluted`	$-0.89	USD	1 Quarter
Net loss per share, basic and diluted (in dollars)	`EarningsPerShareBasicAndDiluted`	$-0.90	USD	1 Quarter
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	1.70M	shares	1 Quarter
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	3.69M	shares	1 Quarter

Cash Flow Statement 37 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-1.51M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-3.32M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$170.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$157.00K	USD	1 Quarter
Amortization of right of use assets	`OperatingLeaseRightOfUseAssetsAmortization`	$19.00K	USD	1 Quarter
Amortization of right of use assets	`OperatingLeaseRightOfUseAssetsAmortization`	$28.00K	USD	1 Quarter
Depreciation	`Depreciation`	$66.00K	USD	1 Quarter
Depreciation	`Depreciation`	$18.00K	USD	1 Quarter
Prepaid drug product for testing	`IncreaseDecreaseInPrepaidExpense`	$95.00K	USD	1 Quarter
Prepaid drug product for testing	`IncreaseDecreaseInPrepaidExpense`	$-12.00K	USD	1 Quarter
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$570.00K	USD	1 Quarter
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-250.00K	USD	1 Quarter
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-54.00K	USD	1 Quarter
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$341.00K	USD	1 Quarter
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$21.00K	USD	1 Quarter
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$28.00K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.54M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.01M	USD	1 Quarter
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$900.00K	USD	Point-in-time
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$19.41M	USD	1 Quarter
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$17.00M	USD	Point-in-time
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$1.50M	USD	Point-in-time
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	1 Quarter
Net proceeds from exercise of warrants	`ProceedsFromStockOptionsExercised`	-	USD	1 Quarter
Net proceeds from exercise of warrants	`ProceedsFromStockOptionsExercised`	$869.00K	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	-	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$20.28M	USD	1 Quarter
Net increase (decrease) in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$18.27M	USD	1 Quarter
Net increase (decrease) in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-2.54M	USD	1 Quarter
Cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.00M	USD	Point-in-time
Cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$19.28M	USD	Point-in-time
Cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$20.43M	USD	Point-in-time
Cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$17.89M	USD	Point-in-time
Cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.00M	USD	Point-in-time
Cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$19.28M	USD	Point-in-time
Cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$20.43M	USD	Point-in-time
Cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$17.89M	USD	Point-in-time

Stockholders Equity 14 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance	`StockholdersEquity`	$21.09M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$17.93M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$20.14M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$1.22M	USD	Point-in-time
Issuance of common stock, net of fees	`StockIssuedDuringPeriodValueNewIssues`	$19.41M	USD	1 Quarter
Exercise of warrants, net of fees	`StockIssueDuringPeriodValueWarrantsExercised`	$869.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalOther`	$157.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalOther`	$170.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.51M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-3.32M	USD	1 Quarter
Ending Balance	`StockholdersEquity`	$21.09M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$17.93M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$20.14M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$1.22M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.